Clinical Network Services appoints leading toxicologist to BioDesk
05 March, 2013Clinical Network Services has appointed toxicologist Dr Doug Francis to its BioDesk consultancy.
Alchemia completes recruitment for colorectal cancer trial
05 March, 2013 by Susan WilliamsonAlchemia (ASX:ACL) has completed enrolment of 415 patients for its Phase III trial of HA-Irinotecan in metastatic colorectal cancer.
Nominations invited for gene technology committees
05 March, 2013The Office of the Gene Technology Regulator is seeking nominations for membership of the Gene Technology Technical Advisory Committee and the Gene Technology Ethics and Community Consultative Committee.
Prima Biomed begins recruitment in Europe
05 March, 2013 by Susan WilliamsonPrima BioMed (ASX:PRR) has begun recruiting patients into its ovarian cancer vaccine trial in Europe.
Starpharma seeks patent for dendrimer cancer drug
05 March, 2013 by Dylan Bushell-EmblingSuccessful animal trials of dendrimer-doxorubicin have prompted Starpharma (ASX:SPL) to file for a patent for the formula in preparation for partnership negotiations.
Bionomics to raise $16.4m in rights issue
04 March, 2013 by Dylan Bushell-EmblingBionomics (ASX:BNO) has launched a 1-for-8 rights issue to help raise cash for its drug development programs and improve its ability to independently fund clinical trials.
Major medtech event to feature in Melbourne
28 February, 2013 by AusBiotechThe AusMedtech national medtech conference, now its sixth year, will for the first time be held in Melbourne in May.
Bionomics preps for capital raising
28 February, 2013 by Tim DeanBionomics (ASX:BNO) has entered a trading halt ahead of a capital raising.
Alchemia reaps $4.4m from R&D Tax Incentive
27 February, 2013 by Tim DeanAlchemia (ASX:ACL) has received a payout under the R&D Tax Incentive scheme that has principally covered expenses related to phase III clinical trials.
AtCor signs $800K contract expansion
25 February, 2013 by Tim DeanAtCor Medical (ASX:ACG) has expanded an existing contract to supply its SphygmoCor diagnostic to the tune of $800,000.
Industry comments on ANZTPA’s joint framework
25 February, 2013 by AusBiotechAusBiotech has made a submission on behalf of the biotechnology industry to the Australia New Zealand Therapeutic Products Agency’s (ANZTPA) discussion paper.
AtCor swings to profit
22 February, 2013 by Dylan Bushell-EmblingAtCor Medical (ASX:ACG) has reported its second ever half-year profit for 1H13 thanks to revenue growth and cost-cutting.
AusBiotech commends Productivity Commission’s draft report on compulsory licensing of patents
21 February, 2013 by AusBiotechAusBiotech has commended the “thorough work of commission and its December 2012 ‘Draft Report’ on Compulsory Licensing of Patents”.
Movers & shakers: Another Farrell to head ResMed
21 February, 2013 by Tim DeanMick Farrell, son of Dr Peter Farrell, will take over as CEO of ResMed while his father transitions to non-executive chairman.
PolyActiva $9.2m cash injection
20 February, 2013 by Tim DeanPolyActiva has raised $9.2m to further the development of its polymer drug delivery technology platform.
